Peripheral iris thickness associated with ITC in PAC

Article

Peripheral iris thickness is associated with iridotrabecular contact (ITC) in those who have angle closure, according to new research out of Japan.

Peripheral iris thickness is associated with iridotrabecular contact (ITC) in those who have angle closure, according to new research out of Japan.

The investigators prospectively recruited patients with primary angle closure (PAC) and PAC glaucoma addressed with laser peripheral iridotomy (LPI). They performed anterior segment optical coherence tomography (AS-OCT) under light and dark conditions and took scans along the vertical and horizontal axes.

They used software to measure iris thickness at 500 µm (IT500) and 750 µm (IT750) from the scleral spur, maximal iris thickness (MIT) and cross sections of the iris area (I-Area). The investigators defined ITC by ASOCT as the contact between the peripheral iris and angle wall anterior to the scleral spur. They defined the ITC+ group as eyes having ITC in 2 or more quadrants and the ITC- group as eyes having ITC in 0 or 1 quadrant.

The researchers examined 79 eyes of 60 patients; 48 had PAC and 31 had PACG. They found superior ITC in 44 eyes (55.7%), inferior ITC in 48 eyes (60.8%), temporal ITC in 18 eyes (22.8%), and nasal ITC in 16 eyes (20.2%). For analysis, they used the iris parameters of the inferior quadrant, which had the highest prevalence of all the quadrants.

The investigators adjusted for age, sex, pupil size and central anterior chamber depth and found that mean values of IT500 and IT750 were significantly greater in the ITC+ group than in the ITC- group (P + group compared with the ITC- group, per 0.1-unit increase, were 1.9 for IT500 (P = 0.029); 2.0 for IT750 (P = 0.011), 1.4 for MIT (P = 0.244), and 0.97 for I-Area (P = 0.406), they noted.

"In this study, approximately 40% of patients had ITC in two or more quadrants even after LPI, and peripheral iris thickness was considered to be important for angle-closure pathogenesis," the authors wrote. "To arrive at a definitive conclusion, further investigation is necessary in a larger number of cases in the future."

Read the article in Clinical Ophthalmology.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
© 2025 MJH Life Sciences

All rights reserved.